drugset / Trial / NCT06563986
FTD-TPI, Bevacizumab, and Radioembolization With 166Ho-microspheres in Refractory Metastatic Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
Extrahepatic disease progression limits clinical efficacy of individualized radioembolization for patients with refractory metastatic colorectal cancer (mCRC). In the same patient population, trifluridine/tipiracil (FTD-TPI) and bevacizumab lead to disease control and overall survival benefit and may be a radiosensitizer. The purpose of this study is to determine safety, tolerability, and activity of individualized radioembolization with 166Holmium (166Ho)-microspheres combined with FTD-TPI and bevacizumab.
Timeline
- Start
- 2024-06-18
- Primary completion
- 2028-01
- Completion
- 2028-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 166-Ho microspheres | Unknown | — | Other |
| Background | Bevacizumab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Background | TAS-102 | Small molecule | 35 mg/m2 | Oral |